SPIKE PROTEINS AND HEXAPRO

Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches

Retrieved on: 
Wednesday, March 23, 2022

Vaxxas , a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.

Key Points: 
  • Vaxxas , a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.
  • We can now rapidly advance our clinical trials with our next-generation COVID-19 vaccine patch.
  • Vaxxas plans to complete a Phase 1 clinical study of its proprietary HexaPro/HD-MAP COVID-19 vaccine this year.
  • "The current pandemic has underscored the lifesaving potential of innovative technologies, and we think novel vaccination approaches clearly offer unique benefits.